Single‐cell next‐generation sequencing of circulating tumor cells in patients with neuroblastoma

Kojima, Masato; Harada, Takanori; Fukazawa, Takahiro; Kurihara, Sho; Touge, Ryo; Saeki, Isamu; Takahashi, Shinya; Hiyama, Eiso

doi:10.1111/cas.15707

Cited by 10 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…209 Single-cell next-generation sequencing of CTCs have been adopted for acquiring information encapsulated in CTCs. NB patients with advanced stages expressed ALK mutation (p.F1174L) in both tumor tissue and CTC as well as more angiogenesisrelated, cell cycle-related genes, CCND1 and TUBA1A genes, 215 which showcasing the importance for guiding clinical decision-making.…”

Section: Neuroblastomamentioning

confidence: 99%

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Bao,

Min,

et al. 2023

Interdisciplinary Medicine

View full text Add to dashboard Cite

Liquid biopsy has emerged as a promising avenue for non‐invasive and rapid retrieval of pathological information from patient body fluids. Over the years, liquid biopsy has garnered significant attention for clinically treating cancer by selecting appropriate biomarkers such as circulating tumor cells (CTCs) and extracellular vesicles (EVs). Further integration of advanced technologies has facilitated the efficient capture of biomarkers for liquid biopsy, revolutionizing clinical decision‐making in the multiple processes and stages of cancer patients. Underscoring the intersection of different disciplines, this review provides a holistic summary of recent breakthroughs specifically designed for the capture and application of distinctive biomarkers to blend real‐world clinical decision‐making with material science. Firstly, we focus on the main principles of liquid biopsy and recent technologies that facilitate the capture and release of biomarkers (e.g., CTCs and EVs), leveraging their physicochemical properties. Then, the clinical applications of biomarkers are summarized, highlighting their potential for providing comprehensive clinical information. Later, the incorporation of machine learning is also emphasized for enhancing clinical applications and enabling deeper insights in the design of next‐generation platforms for specific biomarker isolation. Finally, future opportunities for clinical decision‐making are explored by combining advanced nanotechnologies and artificial intelligence, thereby offering inconceivable possibilities for improving patient care.

show abstract

Section: Neuroblastomamentioning

confidence: 99%

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Bao,

Min,

et al. 2023

Interdisciplinary Medicine

View full text Add to dashboard Cite

show abstract

“…126,[193][194][195] Mutation or copy number variation of some cancer-related genes (ALK, RB1, SMAD4, MYCN) reported using single-cell sequencing on CTCs in neuroblastoma (NB) patients. 196 Sanger sequencing. The Sanger dideoxynucleotide sequencing method was first developed over 40 years ago as an enzymatic technology for DNA…”

Section: Genomic Characterizationmentioning

confidence: 99%

“…126,193–195 Mutation or copy number variation of some cancer-related genes ( ALK, RB1, SMAD4, MYCN ) reported using single-cell sequencing on CTCs in neuroblastoma (NB) patients. 196…”

Section: Novel Approaches In Ctc Characterizationmentioning

confidence: 99%

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA

Yaghoubi Naei,

Bordhan,

Mirakhorli

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced significantly. They have received recognition for their clinical usefulness in detecting cancer at an early stage, monitoring disease, and evaluating treatment response. The emergence of liquid biopsy has been a helpful development, as it offers a minimally invasive, rapid, real-time monitoring, and possible alternative to traditional tissue biopsies. In resource-limited settings, the ideal platform for liquid biopsy should not only extract more CTCs or ctDNA from a minimal sample volume but also accurately represent the molecular heterogeneity of the patient’s disease. This review covers novel strategies and advancements in CTC and ctDNA-based liquid biopsy platforms, including microfluidic applications and comprehensive analysis of molecular complexity. We discuss these systems’ operational principles and performance efficiencies, as well as future opportunities and challenges for their implementation in clinical settings. In addition, we emphasize the importance of integrated platforms that incorporate machine learning and artificial intelligence in accurate liquid biopsy detection systems, which can greatly improve cancer management and enable precision diagnostics.

show abstract

“…Moreover, CTCs contain DNA, RNA and proteins (23) that aid in enhancing our understanding of their malignant biology. Recently, we identified the up-regulation of angiogenesis-and cell cycle-related genes in neuroblastoma CTCs by single-cell RNA sequencing and a subgroup of CTCs with highly proliferative features in a patient with neuroblastoma (24). CTCs exist in the blood as single cells or clusters, and in breast cancer, CTC clusters have 20-100 times higher metastatic potential than single CTCs (25).…”

Section: Future Perspectives and Challenges In Unveiling The Malignan...mentioning

confidence: 99%

Circulating Tumor Cells and Tumor Progression, Metastasis, and Poor Prognosis in Patients With Neuroblastoma

KOJIMA,

HIYAMA

2023

Anticancer Res

View full text Add to dashboard Cite

Neuroblastoma is the most common extracranial solid tumor in children, and the overall survival rate of patients in the high-risk group is less than 50%. Circulating tumor cells have recently been found to be a potential source of tumor progression, metastasis, and poor prognosis in patients with cancer. There is a dearth of data on the malignant potential of circulating tumor cells in neuroblastoma. Therefore, in this article, we briefly review the methods of quantifying circulating neuroblastoma cells and the relationship between the presence of many circulating tumor cells and prognosis for patients with neuroblastoma. The relationship between higher numbers of circulating neuroblastoma tumor cells and poor prognosis was outlined. However, the data in most studies represented only the tumor burden, and there is no direct evidence that circulating tumor cells are the source of tumor progression and metastasis in patients with neuroblastoma. A comprehensive genetic analysis of circulating tumor cells, including single-cell sequencing and functional assays using ex vivo cell culture and xenografts, may provide insights into the malignant nature of neuroblastoma.Neuroblastomas are the most common type of extracranial solid tumor in children, accounting for ~13% of all pediatric malignancy-related deaths (1). Neuroblastomas are characterized by wide clinical heterogeneity that results in varied clinical presentations, ranging from spontaneous regression to aggressive progression. The overall survival rate of patients in the high-risk group is less than 50% (2).Circulating tumor cells (CTCs) passively or actively migrate into the blood from primary tumor sites and metastases. Most CTCs die in the blood due to shear stress, anoikis, and immune reactions, but subgroups of CTCs have a metastasis-initiating capacity (3-5). Epithelial-mesenchymal transition (EMT) is a well-known biological mechanism associated with CTCs, and EMT in tumors has been associated with metastasis and poor prognosis (4) (Figure 1). This review focused on the malignant biology and prognostic value of CTCs in neuroblastoma. Moreover, future perspectives on the molecular analysis of CTCs in neuroblastoma are also discussed.

show abstract

Single‐cell next‐generation sequencing of circulating tumor cells in patients with neuroblastoma

Cited by 10 publications

References 26 publications

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision‐making

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA

Circulating Tumor Cells and Tumor Progression, Metastasis, and Poor Prognosis in Patients With Neuroblastoma

Contact Info

Product

Resources

About